Biopharmaceutical firm Peregrine Pharmaceuticals has closed an offering for $2.9 million shares of its common stock in exchange for $1.8 million from an institutional investor. With the new investment, the Tustin, CA-based firm said it now has $10 million in cash to fund its clinical trials, contract-manufacturing operations, and R&D. The shares were sold pursuant to the company’s shelf registration statement on Form S-3, filed with the U.S. Securities and Exchange Commission.
By AuntMinnie.com staff writersAugust 14, 2002
Related Reading
Peregrine lands $5.75 million investment, November 19, 2001
Biopharmaceutical firm Peregrine hawks new agents, September 19, 2001
Copyright © 2002 AuntMinnie.com